<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01789203</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00007510</org_study_id>
    <secondary_id>IRB0612-0114</secondary_id>
    <nct_id>NCT01789203</nct_id>
  </id_info>
  <brief_title>Ciprofloxacin for Prevention of BK Infection</brief_title>
  <official_title>Ciprofloxacin for Prevention of BK Infection in Renal Transplant Recipients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Methodist Hospital System</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The Methodist Hospital System</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      BK infection is an important cause of graft dysfunction and graft loss after renal
      transplantation. It has been widely accepted that emergence of BK virus correlates with the
      more potent immunosuppressive agents used to lower acute rejection rates. In contrast to
      other opportunistic infections after transplantation, for which routine prophylactic agents
      are administered, there is no effective agent for the prevention of BK infection. Some data,
      however, suggests that quinolone antibiotics such as ciprofloxacin may have activity against
      BK virus. This has led us to investigate whether routine, short-term ciprofloxacin
      administration post-transplant can lower the incidence of BK infection.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      BK virus is a member of the virus family polyomaviridae (&quot;polyoma&quot;). The virus, which can
      manifest as a viral nephritis, was first described in a renal transplant recipient in 1971,
      however it was not until the past decade that infection with BK virus became known as an
      important contributor to graft dysfunction and graft loss after renal transplantation. It has
      been widely accepted that emergence of BK virus correlates with the more potent
      immunosuppressive agents currently used to lower acute rejection rates. In contrast to other
      opportunistic infections after transplantation, for which routine prophylactic agents are
      administered, there is no effective agent for the prevention of BK infection, nor is there an
      effective agent for treating BK infection once it occurs.

      Ciprofloxacin is a well known anti-infective agent in the fluoroquinolone class of
      antibiotics. It is most active against gram-negative enteric pathogens, and is commonly used
      for a variety of infectious indications.

      Though classified as antibacterial agents, fluoroquinolones have been suggested to exhibit
      anti-BK viral effects by interfering with helicase activity of the BK virus large T antigen.
      Ciprofloxacin has been shown in previous studies to reduce urine BK viral load, and
      BK-associated hemorrhagic cystitis in the stem cell transplant population. Ciprofloxacin has
      also been associated with a lower incidence of BK viremia in one retrospective study in
      kidney transplant recipients. Based on these reports, the investigators hope to find a
      reduction BK viremia and BK nephropathy using a prospective, randomized study design.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 2013</start_date>
  <completion_date type="Actual">October 2017</completion_date>
  <primary_completion_date type="Actual">April 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Patients Developing BK Infection at 6 Months Post-transplant</measure>
    <time_frame>6 months</time_frame>
    <description>Number of patients (followed by proportion) developing BK infection at 6 months post-transplant. BK infection is defined as the presence of a detectable BK viral load in plasma by polymerase chain reaction (PCR), or the presence of BK viral inclusions on kidney biopsy specimens.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With Gram Negative Urinary Tract Infections at 6 Months</measure>
    <time_frame>6 months</time_frame>
    <description>Number of patients with gram negative urinary tract infections as defined by a midstream urine sample containing 10^4 or more colony-forming units per mL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With Bacteremia at 6 Months</measure>
    <time_frame>6 months</time_frame>
    <description>Number of patients with bacteremic infection at 6 months. Bacteremia defined by a single positive blood culture that was not thought to be contaminated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With Quinolone-resistant Infection at 6 Months</measure>
    <time_frame>6 months</time_frame>
    <description>Number of patients with quinolone-resistant gram negative bacterial infections, among those with a gram-negative infection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clostridium Difficile at 6 Months</measure>
    <time_frame>6 months</time_frame>
    <description>Clostridium difficile infection at 6 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serious Adverse Events</measure>
    <time_frame>4 months</time_frame>
    <description>Serious adverse events collected for up to 4 months (3 months on study drug plus 1 additional month)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to BK Infection</measure>
    <time_frame>12 months</time_frame>
    <description>Median time to initial BK viremia episode, days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BK Viremia at 1 Year</measure>
    <time_frame>12 months</time_frame>
    <description>Proportion of patients developing BK viremia at 1 year</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>First Plasma Viral Loads</measure>
    <time_frame>12 months</time_frame>
    <description>First BK plasma viral loads</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute Rejection at 1 Year</measure>
    <time_frame>12 months</time_frame>
    <description>Number of patients with biopsy-proven acute rejection of the allograft at 1 year, based on Banff classification</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Graft Loss at 1 Year</measure>
    <time_frame>12 months</time_frame>
    <description>kidney failure within first 1 year of transplant</description>
  </other_outcome>
  <other_outcome>
    <measure>Death at 1 Year</measure>
    <time_frame>12 months</time_frame>
    <description>Patient death at 1 year</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">200</enrollment>
  <condition>BK Virus Infection</condition>
  <arm_group>
    <arm_group_label>Ciprofloxacin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ciprofloxacin will be administered as two-250 mg capsules, administered once daily for 3 months post-transplant</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching placebo will be administered as two-capsules given once daily for 3 months post-transplant</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ciprofloxacin</intervention_name>
    <description>Patients will be randomized 2:1 active comparator, Cipro, to placebo comparator.</description>
    <arm_group_label>Ciprofloxacin</arm_group_label>
    <other_name>Cipro</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Patients will be randomized 2:1 placebo comparator to active comparator, Cipro.</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>inactive drug</other_name>
    <other_name>innocuous medication</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female subjects over the age of 18 years

          -  Recipients of a primary or repeat renal allograft either alone (from a deceased or
             living donor) or as a dual-kidney transplant

          -  Signed informed consent form prior to any research assessment

        Exclusion Criteria:

          -  Patients with known severe allergy to ciprofloxacin

          -  History of tendon rupture or tendinitis

          -  Use of antiarrythmic drugs known to prolong the QT interval such as class IA
             antiarrhythmic drugs (e.g. quinidine, procainamide, disopyramide), class III
             antiarrhythmic drugs (e.g. amiodarone, sotalol)

          -  Patients with history of previous non-renal transplantation

          -  Recipients administered rituximab within one year prior to transplantation, or
             recipients expected to receive rituximab as part of desensitization strategy or for
             the presence of historical donor specific antibodies

          -  QTc interval interval of greater than 500 msec on admission or post-operative EKG

          -  BK nephropathy with previous transplant

          -  BK viremia on admission

          -  Any condition present during the initial transplant hospitalization that in the
             investigator's judgment would increase the risk associated with participation in the
             study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Samir J Patel, Pharm.D.</last_name>
    <role>Study Chair</role>
    <affiliation>Clinical Pharmacist</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ahmed O Gaber, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Director, Houston Methodist Transplant Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Houston Methodist Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Brennan DC, Agha I, Bohl DL, Schnitzler MA, Hardinger KL, Lockwood M, Torrence S, Schuessler R, Roby T, Gaudreault-Keener M, Storch GA. Incidence of BK with tacrolimus versus cyclosporine and impact of preemptive immunosuppression reduction. Am J Transplant. 2005 Mar;5(3):582-94. Erratum in: Am J Transplant. 2005 Apr;5(4 Pt 1):839.</citation>
    <PMID>15707414</PMID>
  </reference>
  <reference>
    <citation>Ali SH, Chandraker A, DeCaprio JA. Inhibition of Simian virus 40 large T antigen helicase activity by fluoroquinolones. Antivir Ther. 2007;12(1):1-6.</citation>
    <PMID>17503741</PMID>
  </reference>
  <reference>
    <citation>Leung AY, Chan MT, Yuen KY, Cheng VC, Chan KH, Wong CL, Liang R, Lie AK, Kwong YL. Ciprofloxacin decreased polyoma BK virus load in patients who underwent allogeneic hematopoietic stem cell transplantation. Clin Infect Dis. 2005 Feb 15;40(4):528-37. Epub 2005 Jan 21.</citation>
    <PMID>15712075</PMID>
  </reference>
  <reference>
    <citation>Miller AN, Glode A, Hogan KR, Schaub C, Kramer C, Stuart RK, Costa LJ. Efficacy and safety of ciprofloxacin for prophylaxis of polyomavirus BK virus-associated hemorrhagic cystitis in allogeneic hematopoietic stem cell transplantation recipients. Biol Blood Marrow Transplant. 2011 Aug;17(8):1176-81. doi: 10.1016/j.bbmt.2010.12.700. Epub 2010 Dec 23.</citation>
    <PMID>21185389</PMID>
  </reference>
  <reference>
    <citation>Gabardi S, Waikar SS, Martin S, Roberts K, Chen J, Borgi L, Sheashaa H, Dyer C, Malek SK, Tullius SG, Vadivel N, Grafals M, Abdi R, Najafian N, Milford E, Chandraker A. Evaluation of fluoroquinolones for the prevention of BK viremia after renal transplantation. Clin J Am Soc Nephrol. 2010 Jul;5(7):1298-304. doi: 10.2215/CJN.08261109. Epub 2010 May 27.</citation>
    <PMID>20507960</PMID>
  </reference>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>February 7, 2013</study_first_submitted>
  <study_first_submitted_qc>February 11, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 12, 2013</study_first_posted>
  <results_first_submitted>April 2, 2019</results_first_submitted>
  <results_first_submitted_qc>October 25, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">November 13, 2019</results_first_posted>
  <last_update_submitted>October 25, 2019</last_update_submitted>
  <last_update_submitted_qc>October 25, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 13, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The Methodist Hospital System</investigator_affiliation>
    <investigator_full_name>Ahmed Osama Gaber, MD</investigator_full_name>
    <investigator_title>Director, Houston Methodist Transplant Center</investigator_title>
  </responsible_party>
  <keyword>BK infection</keyword>
  <keyword>BK viremia</keyword>
  <keyword>BK nephropathy</keyword>
  <keyword>polyomavirus</keyword>
  <keyword>fluoroquinolone</keyword>
  <keyword>ciprofloxacin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ciprofloxacin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>March 30, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/03/NCT01789203/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Ciprofloxacin</title>
          <description>Ciprofloxacin will be administered as two-250 mg capsules, administered once daily for 3 months post-transplant
Ciprofloxacin: Patients will be randomized 2:1 active comparator to placebo comparator.</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Matching placebo will be administered as two-capsules given once daily for 3 months post-transplant
placebo</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="133"/>
                <participants group_id="P2" count="67"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="124"/>
                <participants group_id="P2" count="63"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>patient non-adherent</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Analysis performed on IIT patients (all randomized patients)</population>
      <group_list>
        <group group_id="B1">
          <title>Ciprofloxacin</title>
          <description>Ciprofloxacin will be administered as two-250 mg capsules, administered once daily for 3 months post-transplant
Ciprofloxacin: Patients will be randomized 2:1 active comparator to placebo comparator.</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Matching placebo will be administered as two-capsules given once daily for 3 months post-transplant
placebo</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="133"/>
            <count group_id="B2" value="67"/>
            <count group_id="B3" value="200"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49" lower_limit="40" upper_limit="58"/>
                    <measurement group_id="B2" value="44" lower_limit="37" upper_limit="57"/>
                    <measurement group_id="B3" value="48" lower_limit="39" upper_limit="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="54"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="74"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="79"/>
                    <measurement group_id="B2" value="47"/>
                    <measurement group_id="B3" value="126"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other or Unknown</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Repeat Transplant</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Patients Developing BK Infection at 6 Months Post-transplant</title>
        <description>Number of patients (followed by proportion) developing BK infection at 6 months post-transplant. BK infection is defined as the presence of a detectable BK viral load in plasma by polymerase chain reaction (PCR), or the presence of BK viral inclusions on kidney biopsy specimens.</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ciprofloxacin</title>
            <description>Ciprofloxacin will be administered as two-250 mg capsules, administered once daily for 3 months post-transplant
Ciprofloxacin: Patients will be randomized 2:1 active comparator to placebo comparator.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matching placebo will be administered as two-capsules given once daily for 3 months post-transplant
placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients Developing BK Infection at 6 Months Post-transplant</title>
          <description>Number of patients (followed by proportion) developing BK infection at 6 months post-transplant. BK infection is defined as the presence of a detectable BK viral load in plasma by polymerase chain reaction (PCR), or the presence of BK viral inclusions on kidney biopsy specimens.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="133"/>
                <count group_id="O2" value="67"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With Gram Negative Urinary Tract Infections at 6 Months</title>
        <description>Number of patients with gram negative urinary tract infections as defined by a midstream urine sample containing 10^4 or more colony-forming units per mL</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ciprofloxacin</title>
            <description>Ciprofloxacin will be administered as two-250 mg capsules, administered once daily for 3 months post-transplant
Ciprofloxacin: Patients will be randomized 2:1 active comparator to placebo comparator.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matching placebo will be administered as two-capsules given once daily for 3 months post-transplant
placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Gram Negative Urinary Tract Infections at 6 Months</title>
          <description>Number of patients with gram negative urinary tract infections as defined by a midstream urine sample containing 10^4 or more colony-forming units per mL</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="133"/>
                <count group_id="O2" value="67"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With Bacteremia at 6 Months</title>
        <description>Number of patients with bacteremic infection at 6 months. Bacteremia defined by a single positive blood culture that was not thought to be contaminated.</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ciprofloxacin</title>
            <description>Ciprofloxacin will be administered as two-250 mg capsules, administered once daily for 3 months post-transplant
Ciprofloxacin: Patients will be randomized 2:1 active comparator to placebo comparator.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matching placebo will be administered as two-capsules given once daily for 3 months post-transplant
placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Bacteremia at 6 Months</title>
          <description>Number of patients with bacteremic infection at 6 months. Bacteremia defined by a single positive blood culture that was not thought to be contaminated.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="133"/>
                <count group_id="O2" value="67"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With Quinolone-resistant Infection at 6 Months</title>
        <description>Number of patients with quinolone-resistant gram negative bacterial infections, among those with a gram-negative infection</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ciprofloxacin</title>
            <description>Ciprofloxacin will be administered as two-250 mg capsules, administered once daily for 3 months post-transplant
Ciprofloxacin: Patients will be randomized 2:1 active comparator to placebo comparator.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matching placebo will be administered as two-capsules given once daily for 3 months post-transplant
placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Quinolone-resistant Infection at 6 Months</title>
          <description>Number of patients with quinolone-resistant gram negative bacterial infections, among those with a gram-negative infection</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clostridium Difficile at 6 Months</title>
        <description>Clostridium difficile infection at 6 months</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ciprofloxacin</title>
            <description>Ciprofloxacin will be administered as two-250 mg capsules, administered once daily for 3 months post-transplant
Ciprofloxacin: Patients will be randomized 2:1 active comparator to placebo comparator.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matching placebo will be administered as two-capsules given once daily for 3 months post-transplant
placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Clostridium Difficile at 6 Months</title>
          <description>Clostridium difficile infection at 6 months</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="133"/>
                <count group_id="O2" value="67"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serious Adverse Events</title>
        <description>Serious adverse events collected for up to 4 months (3 months on study drug plus 1 additional month)</description>
        <time_frame>4 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ciprofloxacin</title>
            <description>Ciprofloxacin will be administered as two-250 mg capsules, administered once daily for 3 months post-transplant
Ciprofloxacin: Patients will be randomized 2:1 active comparator to placebo comparator.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matching placebo will be administered as two-capsules given once daily for 3 months post-transplant
placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Serious Adverse Events</title>
          <description>Serious adverse events collected for up to 4 months (3 months on study drug plus 1 additional month)</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="133"/>
                <count group_id="O2" value="67"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35"/>
                    <measurement group_id="O2" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to BK Infection</title>
        <description>Median time to initial BK viremia episode, days</description>
        <time_frame>12 months</time_frame>
        <population>Included 31 ciprofloxacin and 8 placebo patients who became BK viremic during the first 12 months</population>
        <group_list>
          <group group_id="O1">
            <title>Ciprofloxacin</title>
            <description>Ciprofloxacin will be administered as two-250 mg capsules, administered once daily for 3 months post-transplant
Ciprofloxacin: Patients will be randomized 2:1 active comparator to placebo comparator.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matching placebo will be administered as two-capsules given once daily for 3 months post-transplant
placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Time to BK Infection</title>
          <description>Median time to initial BK viremia episode, days</description>
          <population>Included 31 ciprofloxacin and 8 placebo patients who became BK viremic during the first 12 months</population>
          <units>days</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90" lower_limit="59" upper_limit="160"/>
                    <measurement group_id="O2" value="76.5" lower_limit="59" upper_limit="295"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>BK Viremia at 1 Year</title>
        <description>Proportion of patients developing BK viremia at 1 year</description>
        <time_frame>12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ciprofloxacin</title>
            <description>Ciprofloxacin will be administered as two-250 mg capsules, administered once daily for 3 months post-transplant
Ciprofloxacin: Patients will be randomized 2:1 active comparator to placebo comparator.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matching placebo will be administered as two-capsules given once daily for 3 months post-transplant
placebo</description>
          </group>
        </group_list>
        <measure>
          <title>BK Viremia at 1 Year</title>
          <description>Proportion of patients developing BK viremia at 1 year</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="133"/>
                <count group_id="O2" value="67"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>First Plasma Viral Loads</title>
        <description>First BK plasma viral loads</description>
        <time_frame>12 months</time_frame>
        <population>included 31 ciprofloxacin and 8 placebo patients who became BK viremic during the first year</population>
        <group_list>
          <group group_id="O1">
            <title>Ciprofloxacin</title>
            <description>Ciprofloxacin will be administered as two-250 mg capsules, administered once daily for 3 months post-transplant
Ciprofloxacin: Patients will be randomized 2:1 active comparator to placebo comparator.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matching placebo will be administered as two-capsules given once daily for 3 months post-transplant
placebo</description>
          </group>
        </group_list>
        <measure>
          <title>First Plasma Viral Loads</title>
          <description>First BK plasma viral loads</description>
          <population>included 31 ciprofloxacin and 8 placebo patients who became BK viremic during the first year</population>
          <units>copies/mL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2514" lower_limit="796" upper_limit="8754"/>
                    <measurement group_id="O2" value="1423" lower_limit="724" upper_limit="19619"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Acute Rejection at 1 Year</title>
        <description>Number of patients with biopsy-proven acute rejection of the allograft at 1 year, based on Banff classification</description>
        <time_frame>12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ciprofloxacin</title>
            <description>Ciprofloxacin will be administered as two-250 mg capsules, administered once daily for 3 months post-transplant
Ciprofloxacin: Patients will be randomized 2:1 active comparator to placebo comparator.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matching placebo will be administered as two-capsules given once daily for 3 months post-transplant
placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Acute Rejection at 1 Year</title>
          <description>Number of patients with biopsy-proven acute rejection of the allograft at 1 year, based on Banff classification</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="133"/>
                <count group_id="O2" value="67"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Graft Loss at 1 Year</title>
        <description>kidney failure within first 1 year of transplant</description>
        <time_frame>12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ciprofloxacin</title>
            <description>Ciprofloxacin will be administered as two-250 mg capsules, administered once daily for 3 months post-transplant
Ciprofloxacin: Patients will be randomized 2:1 active comparator, Cipro, to placebo comparator.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matching placebo will be administered as two-capsules given once daily for 3 months post-transplant
placebo: Patients will be randomized 2:1 placebo comparator to active comparator, Cipro.</description>
          </group>
        </group_list>
        <measure>
          <title>Graft Loss at 1 Year</title>
          <description>kidney failure within first 1 year of transplant</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="133"/>
                <count group_id="O2" value="67"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Death at 1 Year</title>
        <description>Patient death at 1 year</description>
        <time_frame>12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ciprofloxacin</title>
            <description>Ciprofloxacin will be administered as two-250 mg capsules, administered once daily for 3 months post-transplant
Ciprofloxacin: Patients will be randomized 2:1 active comparator to placebo comparator.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matching placebo will be administered as two-capsules given once daily for 3 months post-transplant
placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Death at 1 Year</title>
          <description>Patient death at 1 year</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="133"/>
                <count group_id="O2" value="67"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were collected out through 4 months (3 months of study drug administration + 1 month post- administration). Patients were asked during clinic visits to report any potential ciprofloxacin adverse event from a list of common adverse effects. Additional AEs were collected if reported by clinician. Graft loss and patient death were additionally collected out through 1 year</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Ciprofloxacin</title>
          <description>Ciprofloxacin will be administered as two-250 mg capsules, administered once daily for 3 months post-transplant
Ciprofloxacin: Patients will be randomized 2:1 active comparator to placebo comparator.</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Matching placebo will be administered as two-capsules given once daily for 3 months post-transplant
placebo</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="133"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="35" subjects_at_risk="133"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="67"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="133"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="133"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="67"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>malignant hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="133"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="133"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="67"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="133"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="67"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="133"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="133"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>GI bleed</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="133"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="133"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="133"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Small bowel obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="133"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="133"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="67"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Ascites</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="133"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="133"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="133"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="133"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Hyperkalemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="133"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="67"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Clostridium difficile</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="133"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Cytomegalovirus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="133"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="133"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="133"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Viral syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="67"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Radial nerve palsy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="133"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="67"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="133"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Dysuria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="133"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Hematuria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="133"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="133"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Nonfunctinal nephrostomy tube</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="133"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Urinary leak</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="133"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="133"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="67"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Hematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="133"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Wound infection/complication</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="133"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="67"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>VTE</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="133"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="67"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="108" subjects_at_risk="133"/>
                <counts group_id="E2" subjects_affected="55" subjects_at_risk="67"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="133"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="133"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="133"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="133"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="67"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Edema</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="133"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="133"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Hypomagnesemia</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="133"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="133"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Weight gain</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="133"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="67"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Urinary tract infections</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="133"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="67"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Osteopenia/osteoperosis</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="133"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="67"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Hematuria</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="133"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Proteinuria</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="133"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="67"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Samir Patel</name_or_title>
      <organization>Methodist Hospital</organization>
      <phone>267-808-0577</phone>
      <email>spatel2@houstonmethodist.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

